Arcturus Could Find Its COVID-19 Vaccine Limited To Smaller Markets
The company plans to seek an EUA in Vietnam for ARCT-154, but some analysts have questioned its prospects in major markets like the US.
You may also be interested in...
Phase II/III data for mRNA-1273.211 showed superiority against variants of concern to the original Spikevax, but Moderna’s top competitor has questioned the need for multivalent approaches.
Sanofi/GSK's vaccine is under review in the EU and the UK government has awarded a grant to a company to allow it to increase its production of a key component of mRNA vaccines. Also, EU member states have proposed ways of improving the supply and donation of COVID-19 vaccines, including for those fleeing the conflict in Ukraine. Germany’s InflaRx has reported “encouraging” results with its anti-inflammatory drug vilobelimab in seriously ill patients.
Novavax has already gained its first emergency use authorization for its COVID-19 vaccine, but doubts remain about its manufacturing and Omicron readiness.